Your session is about to expire
← Back to Search
Behavioural Intervention
tVNS for Atrial Fibrillation (STOP_AF Trial)
N/A
Recruiting
Led By Stavros Stavrakis, MD, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥ 18 years.
Patients scheduled to undergo coronary artery bypass surgery, major vascular/aneurysm repair requiring bypass, valvular replacement or repair, or both, for clinically indicated reasons.
Must not have
Recurrent vasovagal syncope
Known channelopathy such as Brugada syndrome, long QT syndrome, or Catecholaminergic monomorphic ventricular tachycardia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 12 hours of arrival to the icu after surgery and on postop day 3 (2 days)
Summary
This trial tests if using electrical pulses on a nerve in the ear can prevent irregular heartbeats in patients after heart surgery. The treatment aims to reduce inflammation and help the heart beat regularly.
Who is the study for?
This trial is for adults over 18 who are scheduled for cardiac surgery and currently have a normal heart rhythm. They must be willing to follow the study procedures. People with certain heart conditions, pregnant women, those on chronic amiodarone therapy or with complex congenital heart disease, among others, cannot participate.
What is being tested?
The trial is testing if non-invasive transcutaneous vagal nerve stimulation (tVNS) can reduce the occurrence of atrial fibrillation after cardiac surgery and shorten hospital stays. Participants will receive either active tVNS or a sham (fake) treatment as a comparison.
What are the potential side effects?
While specific side effects of tVNS are not detailed here, similar treatments may cause local discomfort at the site of stimulation, headache, voice changes or hoarseness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I am scheduled for major heart or blood vessel surgery.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had multiple fainting spells.
Select...
I have a diagnosed heart rhythm disorder.
Select...
I have ongoing or permanent atrial fibrillation.
Select...
I have a complex heart condition present since birth.
Select...
I have a heart pump or have had a heart or lung transplant.
Select...
I am scheduled for a heart rhythm correction procedure.
Select...
I need urgent surgery.
Select...
I expect to use amiodarone.
Select...
I have a slow heartbeat or sinus node issue without a pacemaker.
Select...
I have had surgery to cut the nerves to my stomach.
Select...
I have been using amiodarone for a long time.
Select...
I am not pregnant.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ within 12 hours of arrival to the icu after surgery and on postop day 3 (2 days)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 12 hours of arrival to the icu after surgery and on postop day 3 (2 days)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Atrial Fibrillation
Secondary study objectives
Days of hospitalization
Duration of post-op atrial fibrillation
Heart rate during atrial fibrillation
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Intervention GroupExperimental Treatment1 Intervention
Active tVNS (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to ear at 20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
Group II: Control GroupPlacebo Group1 Intervention
Sham tVNS will be performed by attaching the Parasym device to the ear and setting output to 0. Stimulation will continue until 5 days post-operatively or discharge.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
active tVNS
2019
N/A
~20
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Atrial Fibrillation (AF) include autonomic modulation techniques like transcutaneous vagus nerve stimulation (tVNS), which reduce inflammation and increase the atrial refractory period to stabilize heart rhythm. This is important for AF patients as it can decrease the frequency and severity of AF episodes, reducing the risk of complications such as stroke and heart failure.
Other treatments, such as antiarrhythmic drugs, work by modifying ion channel activity to maintain sinus rhythm, while rate control medications manage heart rate without restoring normal rhythm. Understanding these mechanisms allows for personalized treatment, improving patient outcomes and quality of life.
TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial.The neural basis of atrial fibrillation.
TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial.The neural basis of atrial fibrillation.
Find a Location
Who is running the clinical trial?
University of California, Los AngelesLead Sponsor
1,569 Previous Clinical Trials
10,314,023 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
1 Patients Enrolled for Atrial Fibrillation
University of OklahomaOTHER
474 Previous Clinical Trials
93,425 Total Patients Enrolled
13 Trials studying Atrial Fibrillation
2,342 Patients Enrolled for Atrial Fibrillation
Stavros Stavrakis, MD, PhDPrincipal InvestigatorUniversity of Oklahoma
4 Previous Clinical Trials
563 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
90 Patients Enrolled for Atrial Fibrillation
Jonathan Ho, MDPrincipal InvestigatorUniversity of California, Los Angeles
1 Previous Clinical Trials
120 Total Patients Enrolled
Marmar Vaseghi, MDPrincipal InvestigatorUniversity of California, Los Angeles